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We evaluated the eﬀect of keishibukuryogan (KBG; Guizhi-Fuling-Wan), a traditional Japanese (Kampo) formula, on endothelial
function assessed by reactive hyperemia peripheral arterial tonometry (Endo-PAT2000) in patients with metabolic syndrome-
relatedfactorsbycontrolledclinicaltrialwithcrossoverdesign.Ninety-twopatientswereassignedtogroupA(ﬁrstKBG-treatment
period, then control period; each lasting 4 weeks, with about one-year interval) or group B (ﬁrst control, then KBG-treatment).
In forty-nine (27, group A; 22, group B) patients completing all tests, the mean value of the natural logarithmic-scaled reactive
hyperemia index (L RHI) increased and those of serum nonesteriﬁed fatty acid (NEFA), malondialdehyde, and soluble vascular
cell adhesion molecule 1 decreased signiﬁcantly during the KBG-treatment period, but not during the control period, and 4-week
changes of L RHI, NEFA, and malondialdehyde between the 2 periods showed signiﬁcance. These results suggest that KBG has
beneﬁcial eﬀect on endothelial function in patients with metabolic syndrome-related factors.
1.Introduction
In Japan, the incidence of cardiovascular events has been
increasing on account of the westernization of lifestyle and
increases in the prevalence of overweight and metabolic syn-
drome [1, 2]. Recently, endothelial dysfunction has been rec-
ognized as a crucial pathogenesis in the early stage of arte-
riosclerosis [3, 4]. Traditional risk factors such as hyperten-
sion, dyslipidemia, and hyperglycemia are associated with
endothelial dysfunction [4], and endothelial dysfunction it-
self is also reported to be an independent risk factor in the
development of cardiovascular events [5]. Endothelial dys-
function is reversible, and its improvement can prevent the
development of arteriosclerosis.
Flow-mediated dilatation (FMD) has been used for the
measurement of endothelial function, and by this method
the change of forearm vascular diameter is evaluated by
ultrasonic apparatus [6]. On the other hand, reactive hyper-
emia peripheral arterial tonometry (RH-PAT), a noninvasive
apparatus developed recently, allows easier measurement
compared to FMD [7, 8]. It requires a less-operator-depend-
ent technique, and the inﬂuence of sympathetic nervous
activity in RH-PAT is less than that in FMD. Therefore, it
makes possible the comparison of measured values from dif-
ferent devices.
Keishibukuryogan (KBG; Guizhi-Fuling-Wan) is a tradi-
tional Japanese (Kampo) formula used to prevent the devel-
opment of atherosclerosis. In recent years, we reported the
protective eﬀects of KBG on endothelial function in choles-
terol-fed rabbits and spontaneously diabetic rats [9, 10].
Further, we revealed that KBG actually inhibits the progres-
sion of atherosclerosis in cholesterol-fed rabbits [11, 12].
However, it has not been assessed whether KBG prevents the
progression of atherosclerosis clinically in human subjects,2 Evidence-Based Complementary and Alternative Medicine
and long-term study is not easy to conduct. Therefore, this
time we set out to evaluate the eﬀects of KBG on endothelial
function using RH-PAT in patients with metabolic syn-
drome-related factors by a controlled clinical trial with cros-
sover design.
2. Methods
2.1. Patients. The diagnostic criteria for metabolic syndrome
adopted in the study were deﬁned by the Examination Com-
mittee for Criteria of metabolic syndrome in Japan, that
is, (1) waist circumference ≥85cm in men and ≥90cm in
women; in addition 2 or more of the following 3 com-
ponents: (2) triglyceride (TG) ≥ 150mg/dL and/or high-
density lipoprotein (HDL) cholesterol < 40mg/dL, (3) sys-
tolic blood pressure (SBP) ≥ 130mmHg and/or diastolic
blood pressure (DBP) ≥ 85mmHg, and (4) fasting plasma
glucose (FPG) ≥ 110mg/dL [13]. We recruited patients
aged 40–80 years who were consulting the Department of
Japanese Oriental Medicine, Toyama University Hospital, for
treatment of various diseases or symptoms, and having 1 or
more components of the above diagnostic criteria between
June 2008 and August 2011. Patients with serious liver
or kidney disease, infectious disease, malignancy, previous
stroke or myocardial infarction, or other diseases considered
to possibly disturb the implementation of this trial, were
excluded from enrollment.
2.2. KBG. KBG consists of 5 dried herbal medicines: Cin-
namomi Cortex, Paeoniae Radix, Moutan Cortex, Persicae
Semen, and Hoelen. These herbal powders were mixed with
boiled honey at the ratio shown in Table 1 a n dr o l l e du pi n t o
balls (2g each). All these herbal medicines and honey were
purchased from Uchida Wakanyaku Co. (Tokyo, Japan).
2.3. Study Design. The study was a controlled clinical trial
with crossover design consisting of a 4-week KBG-treatment
period and a 4-week control period. The patients were
randomly assigned into group A (KBG-treatment, period
I; control, period II) or group B (control, period I; KBG-
treatment,periodII).TheFraminghamheartstudyusingthe
FMD technique revealed that ﬂow-mediated vascular dilata-
tion is inﬂuenced by season or temperature and is highest
in summer and lowest in winter [14]. Therefore, we set
both period I and period II in the same season, and the
interval between the 2 periods at about one year. Patients
were evaluated at most 4 times (test 1, beginning of period
I; test 2, end of period I; test 3, beginning of period II; test 4,
end of period II). KBG (6g per day) was administered three
times a day after meals in addition to their usual prescribed
drugsfor4weeksinperiodIingroupAorperiod IIingroup
B.Theseconcomitantdrugshadnotbeenchangedforatleast
3 months before the beginning point of and during period I
and period II (Figure 1). This study was an open-label study,
as it was impossible to prepare a suitable placebo due to the
unique ﬂavor and taste of KBG.
The study design was approved by the Ethics Committee,
UniversityofToyama.Allpatientsprovidedwritteninformed
Table 1: Herbal medicines composing KBG and their ratio.
Herbal medicine Ratio (g)
Cinnamomi Cortex Cinnamomum cassia
BLUME Guizhi 0.2
Paeoniae Radix Paeonia lactiﬂora
PALLAS Shaoyao 0.2
Moutan Cortex Paeonia suﬀruticosa
ANDREWS Mudanpi 0.2
Persicae Semen Prunus persica BATSCH Taoren 0.2
Hoelen Poria cocos WOLF Fuling 0.2
KBG: keishibukuryogan.
These 5 herbal powders were mixed with boiled honey (1g) and rolled up
into balls (2g each).
consent in accordance with the ethical guidelines set forth in
the 1975 Declaration of Helsinki.
2.4. RH-PAT. Endothelial function was evaluated by Endo-
PAT2000 (Itamar Medical, Caesarea, Israel). The principle of
RH-PAT has been described previously [7, 8, 15]. Brieﬂy, a
blood pressure cuﬀ was placed on one upper arm, while the
contralateral arm served as control. PAT probes were placed
on one ﬁnger (ﬁnger II or III) of each hand (same ﬁnger
on both hands). After a 5-minute equilibration period, the
cuﬀ was inﬂated to the higher of either 60mmHg above
systolic pressure or 200mmHg for 5min and then deﬂated
to induce reactive hyperemia. PAT signals were recorded
electronically in both ﬁngers. During these procedures, the
subject was requested to remain quiet and still, and the room
temperature was controlled at 21–24◦C. The RH-PAT data
were analyzed by computer with Endo-PAT2000 software
version 3.1.2 in an operator-independent manner. The PH-
PAT index reﬂects the extent of reactive hyperemia and was
calculated as the ratio of the average amplitude of PAT signal
over 1min starting 1.5min after cuﬀ deﬂation (hyperemic
ﬁnger, A; control ﬁnger, C) divided by the average amplitude
of the PAT signal of a 2.5-minute duration before cuﬀ
inﬂation (baseline, hyperemic ﬁnger, B; control ﬁnger, D).
Then, the reactive hyperthermia index (RHI) was obtained
fromthisequation:RHI=(A/B)/(C/D) ×baselinecorrection
factor. Recently, the natural logarithmic scaled RHI (L RHI)
has often been used instead of RHI [4, 15, 16], and we also
used it in this study (Figure 2).
2.5. Physical Findings and Laboratory Data. Immediately be-
fore the examination of RH-PAT, patients were evaluated for
physical ﬁndings, such as height (HT), body weight (BW),
waist circumference, and SBP and DBP after 5-minute rest at
supine position. Body mass index (BMI) was also calculated
(BMI = BW (kg)/HT (m)
2).
Blood was collected from the cubital vein after overnight
fasting immediately after the RH-PAT examination, and par-
tially separated serum was frozen at −80◦C immediately and
stored until assay. Routine clinical laboratory data, such as
TG, HDL-cholesterol, low-density lipoprotein (LDL) choles-
terol, FPG, immunoreactive insulin (IRI), creatinine, and
high-sensitive C-reactive protein (hs-CRP), were measuredEvidence-Based Complementary and Alternative Medicine 3
Enrollment (n = 100)
Excluded (n = 8)
Quasi-randomization (n = 92)
Group A Group B
Entry to period I (n = 46) Entry to period I (n = 46)
Test 1 (n = 46) Test 1 (n = 46)
KBG-treatment period
of 4 weeks
Control period
of 4 weeks Excluded (n = 6) Excluded (n = 5)
Test 2 (n = 40) Test 2 (n = 41)
Completion of period I (n = 40) Completion of period I (n = 41)
Interval
of about 1 year
Interval
of about 1 year Withdrawn (n = 10) Withdrawn (n = 12)
Entry to period II (n = 30) Entry to period II (n = 29)
Test 3 (n = 30) Test 3 (n = 29)
Excluded (n = 3) Excluded (n = 7)
Test 4 (n = 27) Test 4 (n = 22)
Completion of period II (n = 27) Completion of period II (n = 22)
Control period
of 4 weeks
KBG-treatment period
of 4 weeks
Figure 1: Flow chart of patients enrolled in the study.
by standard laboratory techniques in our hospital. Home-
ostasis model assessment as an index of insulin resistance
(HOMA-IR) was performed for the evaluation of insulin
resistance: [HOMA-IR = IRI (μU/mL) × FPG (mg/dL)/405]
[17]. Nonesteriﬁed fatty acid (NEFA; free fatty acid) was
measured by enzyme method at Mitsubishi Chemical Medi-
ence Co., Tokyo, Japan. We measured malondialdehyde
(MDA), a marker of oxidative stress, by thiobarbituric acid
reactive substance (TBARS) assay kit (OXI-TEK TBARS
Assay Kit; ZeptoMetrix Co., New York, USA), and soluble
vascular cell adhesion molecule 1 (sVCAM-1) by Human
sVCAM-1 Quantikine ELISA Kit (R&D Systems Inc., Min-
neapolis, USA) in our laboratory.
2.6. Statistical Analysis. Statistical analysis was performed
with JMP 9 (SAS Institute Japan, Tokyo). Data were ex-
pressed as mean ± S.E. Either Wilcoxon test or Pearson’s chi-
square test was used for statistical analysis of the patient’s
characteristics. The diﬀerence between the data at week 0
and week 4 was analyzed using the Wilcoxon matched-pairs
signed-ranks test. Comparison between the change of values
in KBG-treatment period and control period was performed
by MANOVA test. A value of P<0.05 was considered sta-
tistically signiﬁcant.
3. Results
3.1.Patients. Intotal,100patientswereinitiallyenrolled,but
8 were then excluded (6, deviation from inclusion criteria;
2, consent withdrawn), and 92 patients were ﬁnally quasi-
randomized to group A (n = 46) and group B (n = 46), and
entered into period I (Figure 1).
In group A, after test 1, 6 patients were excluded [3,
refusedintakeofKBG;1,adverseeﬀect(glossalgia);1,change
of concomitant drug; 1, eating before test], and after the
4-week KBG-treatment period the remaining 40 patients
underwenttest2andcompletedperiodI.Duringtheinterval
of about 1 year between periods I and II, 10 patients dropped
out (7, refused to participate; 2, onset of other disease; 1,
discontinued hospital visit). The other 30 patients entered
into period II and underwent test 3. After that, 3 patients
were excluded (1, onset of infectious disease; 2, change of
concomitant drug), and after the 4-week control period, the
remaining 27 patients underwent test 4 and completed per-
iod II.4 Evidence-Based Complementary and Alternative Medicine
(a)
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Hyperemic
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Control
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Control
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(b)
Baseline Unilateral cuﬀ Hyperemia
5 min occlusion
Figure 2: Representative signals of reactive hyperemia peripheral
arterial tonometry (RH-PAT) with (a) normal and (b) low-reactive
hyperemic response. Normal response characterized by a distinct
increase in the signal amplitude after cuﬀ release compared with
baseline.
In group B, after test 1, 5 patients were excluded (3, re-
fused to participate; 1, onset of infectious disease; 1, eating
before test), and after the 4-week control period, the re-
maining 41 patients underwent test 2 and completed period
I. During the interval between periods I and II, 12 patients
dropped out (7, refused to participate; 1, onset of other
disease; 4, discontinued hospital visit), and the other 29
patients entered into period II and underwent test 3. After
that, 7 patients were excluded (2, adverse eﬀects (diarrhea,
mouth bitterness); 4, change of concomitant drug; 1, eating
before test), and after the 4-week KBG-treatment period,
the remaining 22 patients underwent test 4 and completed
period II.
3.2. Patient Characteristics. The baseline characteristics of
the patients who completed all the tests are shown in Table 2.
A statistical diﬀerence between the 2 groups was seen in male
waist circumference, but not in any of the other factors.
3.3.EﬀectsofKBG. Comparisonbetweenvariousparameters
at week 0 and week 4 in both the KBG-treatment period and
controlperiodandthatof4-weekchangesbetweentheKBG-
treatment period and control period in patients completing
all tests (49 patients in group A + B, 27 in group A plus 22
in group B) are shown in Table 3.T h em e a nv a l u eo fLRHI
in the KBG-treatment period increased signiﬁcantly, but not
in the control period, and the 4-week changes between KBG-
treatmentandcontrolperiodsshowedstatisticalsigniﬁcance.
Further, the mean values of NEFA, MDA, and sVCAM-1
in the KBG-treatment period decreased signiﬁcantly, and 4-
week changes of the former 2 parameters between KBG-
treatment and control periods were statistically signiﬁcant.
Separate data of group A (Table 4)a n dg r o u pB( T a b l e5)
are also shown. In group A, the mean value of L RHI in the
KBG-treatment period increased signiﬁcantly, but not in the
control period, and the 4-week changes between the KBG-
treatmentandcontrolperiodsshowedstatisticalsigniﬁcance.
The mean value of NEFA in the KBG-treatment period
decreased signiﬁcantly, and the 4-week changes between
the KBG-treatment and control periods showed statistical
signiﬁcance. Further, the levels of MDA and sVCAM-1 in
the KBG-treatment period decreased signiﬁcantly. Similarly
in group B, the mean value of L RHI in the KBG-treatment
period increased signiﬁcantly. The levels of NEFA and MDA
in the KBG-treatment period decreased signiﬁcantly, and the
4-week changes of MDA levels between the KBG-treatment
and control periods showed statistical signiﬁcance.
4. Discussion
The risk factors of cardiovascular diseases, such as diabetes
mellitus, hypertension, and dyslipidemia, often accumulate
inthesamepersonandincreasetheincidenceofcardiovascu-
lareventssynergistically.Theconceptofmetabolicsyndrome
arosefroma globalmovementtounifysuchhigh-risk patho-
logicalconditions.InJapanalso,clinicaldiagnosticcriteriaof
metabolicsyndromewereannouncedin2005[13].Endothe-
lial dysfunction is often seen in patients with metabolic syn-
drome, and it is recognized as a primary pathogenic factor
of atherosclerosis [4, 18]. Metabolic syndrome is an inde-
pendent risk factor for cardiovascular events, and if it is
combined with endothelial dysfunction, the risk is elevated
further [19].
Several methods have been developed to evaluate endo-
thelial function, and they enable us to perform the examina-
tion even for outpatients. Evaluation of endothelial function
using FMD or PAT is useful for the early detection of
arteriosclerosis. The RHI calculated using the PAT signal is
applied to a parameter of endothelial function. Endothelial
functioninthebrachialcirculationcorrelateswiththatinthe
coronary circulation, and low RHI is useful for identifying
a patient with coronary endothelial dysfunction [7]. Thus,
PAT is considered to be a useful, noninvasive examination
for the prediction of later cardiovascular events [16]. A value
of RHI ≤ 1.67 (L RHI ≤ 0.51) measured by Endo-PAT2000
is considered to be endothelial dysfunction, is determined
in the population with a risk for ischemic heart disease,
and is recognized as a cut-oﬀ value [20]. The relationship
between RHI and metabolic syndrome-related components
hadbee nr epo rt ed[4].Aspeciﬁccharacteristicofendothelial
function is its reversibility, and it can be a novel therapeutic
target. Studies concerning the eﬀect of drug or supplement
onendothelialfunctionusingRHIhavebeenreportedonthe
basis of its sensitive reaction to treatment [21, 22].
In the present study, we evaluated the endothelial func-
tion of patients with metabolic syndrome-related factors
using RHI by controlled clinical trial with crossover design
and revealed that KBG has the potential to improve endothe-
lial function. That is, L RHI increased signiﬁcantly in the
KBG-treatment period, but not in the control period. It was
reported that patients with lower RHI had a higher incidence
ofcardiovasculareventsduringthefollowupperiod[16],and
improvement of impaired endothelial function is important
for the prevention of the development of arteriosclerosis [3].
Therefore, KBG might be useful for preventing the progres-
sion of endothelial dysfunction and arteriosclerosis. All theEvidence-Based Complementary and Alternative Medicine 5
Table 2: Patient characteristics.
Group A
(n = 27)
Group B
(n = 22) P-value
Age (year) 63.5 ±1.66 2 .0 ±1.7 0.3925a
Sex (male/female) 11/16 9/13 0.9905b
Smoking (yes/no) 2/25 1/21 0.6740b
Alcohol intake (yes/no) 12/15 11/11 0.6983b
BMI (kg/m2)2 4 .1 ±0.62 2 .8 ±0.6 0.3149a
Waist circumference (cm)
Male 91.5 ±3.18 3 .0 ±1.6 0.0435∗a
Female 81.6 ±1.78 2 .5 ±2.7 0.9649a
SBP (mmHg) 126.3 ±3.2 123.8 ±2.6 0.7096a
DBP (mmHg) 76.3 ±2.57 5 .7 ±2.2 0.5938a
TG (mg/dL) 129.2 ±14.6 128.3 ±14.7 0.6802a
HDL-cholesterol (mg/dL) 65.4 ±3.86 0 .4 ±3.2 0.2515a
FPG (mg/dL) 103.7 ±3.3 101.4 ±2.6 0.9278a
Central obesity (yes/no) 11/16 7/15 0.5193b
High blood pressure (yes/no) 16/11 13/9 0.9905b
Dyslipidemia (yes/no) 12/15 11/11 0.6983b
Hyperglycemia (yes/no) 8/19 7/15 0.8687b
Concomitant drugs
Calcium channel blocker (yes/no) 8/19 7/15 0.8687b
ARB or ACE inhibitor (yes/no) 3/24 4/18 0.4817b
α or β blocker (yes/no) 3/24 1/21 0.4038b
Statin (yes/no) 11/16 8/14 0.7544b
Fibrate (yes/no) 1/26 0/22 0.3618b
Sulfonylurea (yes/no) 3/24 1/21 0.4038b
Thiazolidine analog (yes/no) 3/24 0/22 0.1066b
α-glucosidase inhibitor (yes/no) 2/25 1/21 0.6777b
Antiplatelet drug (yes/no) 1/26 0/22 0.3618b
Season test 1 performed 6/14/5/2 9/5/8/0 0.0682b
(Spring/Summer/Fall/Winter)
BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; TG: triglyceride; HDL: high-density lipoprotein; FPG: fasting plasma
glucose; central obesity, waist circumference ≥ 85cm (male), ≥90cm (female); high blood pressure, SBP ≥ 130mmHg and/or DBP ≥ 85mmHg;
dyslipidemia, TG ≥ 150mg/dL and/or HDL cholesterol < 40mg/dL; hyperglycemia, FPG ≥ 110mg/dL; ARB: angiotensin II receptor blocker; ACE:
angiotensin-converting enzyme; Spring: March 21 to June 20; Summer: June 21 to September 21; Fall: September 21 to December 20; Winter: December 21
to March 20.
aComparison between group A and group B by Wilcoxon test.
bComparison between group A and group B by Pearson’s chi-square test.
Data are expressed as mean ± S.E., ∗P<0.05.
patientsenrolledinthisstudywerefreeofobviousﬁndingsof
arteriosclerosis, but endothelial dysfunction (L RHI ≤ 0.51
at test 1) was seen in 37.0% (34/92) of them. Most of the
conventional methods for assessing arteriosclerosis evaluate
its advanced stage. Endothelial dysfunction is observed even
in the initial and early stages of the progression of atheroscle-
rosis. Therefore, an intervention for endothelial dysfunction
by KBG in an as yet latent stage of arteriosclerosis is con-
sidered useful for the prevention of eventual cardiovascular
events.
We have previously reported that KBG improves micro-
circulation evaluated by erythrocyte aggregability and de-
formability in patients with multiple old lacunar infarc-
tion [23, 24]. In experimental animal models, we have
also demonstrated that KBG has protective eﬀects against
endothelial dysfunction in cholesterol-fed rabbits and spon-
taneously diabetic rats [9, 10], in addition to its inhibitory
eﬀect against plaque formation [11, 12]. KBG is composed
of 5 herbal medicines: Cinnamomi Cortex, Paeoniae Radix,
Moutan Cortex, Persicae Semen, and Hoelen. We have6 Evidence-Based Complementary and Alternative Medicine
Table 3: Eﬀects of KBG on various parameters in A + B group (n = 49).
Period Week 0 Week 4 P-valuea P-valueb
BMI (kg/m2) KBG 23.5 ±0.42 3 .5 ±0.5 0.3976
0.3034 Control 23.5 ±0.52 3 .5 ±0.5 0.9700
Waist circumference (cm) KBG 85.0 ±1.28 5 .0 ±1.2 0.9280
0.9136 Control 85.2 ±1.38 5 .3 ±1.3 0.9462
SBP (mmHg) KBG 125.0 ±2.3 121.0 ±2.1 0.0321∗
0.2591 Control 123.1 ±1.9 122.0 ±1.9 0.3629
DBP (mmHg) KBG 74.6 ±1.67 3 .9 ±1.4 0.1297
0.4088 Control 73.2 ±1.47 4 .1 ±1.2 0.5626
L RHI KBG 0.58 ±0.03 0.70 ±0.04 0.0003∗∗
0.0034∗∗
Control 0.64 ±0.04 0.60 ±0.03 0.7279
TG (mg/dL) KBG 124.3 ±8.9 123.2 ±7.8 0.9453
0.5339 Control 125.6 ±8.9 119.1 ±6.2 0.6347
HDL-cholesterol (mg/dL) KBG 62.0 ±2.66 2 .0 ±2.5 0.6699
0.3016 Control 62.6 ±2.16 1 .4 ±2.0 0.1810
LDL-cholesterol (mg/dL) KBG 132.7 ±4.8 133.8 ±5.0 0.5803
0.1155 Control 131.4 ±4.6 127.7 ±5.0 0.0435∗
NEFA (μEq/L) KBG 532.9 ±32.9 450.9 ±26.0 0.0024∗∗
0.0113∗
Control 507.6 ±31.9 529.6 ±29.0 0.3273
FPG (mg/dL) KBG 101.0 ±2.3 101.5 ±2.8 0.9159
0.2087 Control 105.5 ±3.0 103.1 ±3.1 0.1297
IRI (μU/mL) KBG 5.73 ±0.42 5.47 ±0.39 0.2609
0.5396 Control 6.26 ±0.52 6.26 ±0.52 0.9156
HOMA-IR KBG 1.46 ±0.12 1.42 ±0.12 0.3842
0.8010 Control 1.69 ±0.17 1.68 ±0.19 0.8639
Creatinine (mg/dL) KBG 0.71 ±0.02 0.72 ±0.03 0.8238
0.6513 Control 0.71 ±0.02 0.71 ±0.02 1.0000
hs-CRP (mg/dL) KBG 0.13 ±0.05 0.13 ±0.04 0.3721
0.7501 Control 0.11 ±0.03 0.10 ±0.02 0.3173
MDA (nmol/mL) KBG 11.8 ±1.19 .5 ±1.0 <0.0001∗∗
0.0424∗
Control 12.9 ±1.91 2 .3 ±1.9 0.2804
sVCAM-1 (ng/mL) KBG 723.1 ±43.4 677.7 ±40.9 0.0126∗
0.1659 Control 724.3 ±36.0 714.0 ±36.3 0.8107
KBG: keishibukuryogan; BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; L RHI: natural logarithmic scaled reactive
hyperemia; TG: triglyceride; HDL: high-density lipoprotein; LDL: low-density lipoprotein; NEFA: nonesteriﬁed fatty acid; FPG: fasting plasma glucose;
IRI: immunoreactive insulin; HOMA-IR: homeostasis model assessment as an index of insulin resistance; hs-CRP: high-sensitive C-reactive protein;M D A :
malondialdehyde; sVCAM-1: soluble vascular cell adhesion molecule 1.
aComparison between week 0 and week 4 by Wilcoxon matched-pairs signed-ranks test.
bComparison of 4-week changes between KBG-treatment period and control period by MANOVA test.
Data are expressed as mean ± S.E., ∗P<0.05, ∗∗P<0.01.
reported that polyphenols of Cinnamomi Cortex and Paeo-
niae Radix have endothelium-dependent relaxative eﬀects
[25, 26]. Cinnamaldehyde contained in Cinnamomi Cortex
also has endothelium-dependent relaxation eﬀect [27, 28].
These eﬀects of KBG and composing herbal medicines are
assumed to contribute to the eﬃcacy of KBG on endothelial
function.
It is reported that the elevated level of NEFA is related to
metabolic syndrome and endothelial dysfunction, and that it
is an independent predictive factor for cardiovascular events
[29]. In our previous study, KBG decreased the plasma level
of NEFA in cholesterol-fed rabbits [30], and in the present
clinical trial, NEFA was also decreased. Therefore, KBG
seems to have the actual potential to decrease NEFA, and this
eﬀect might contribute to the improvement of endothelial
function.
In the present study, the levels of MDA decreased. Oxida-
tive stress has been reported to impair endothelial function
and accelerate the progression of atherosclerosis. A highly
oxidized condition aggravates endothelial dysfunction and
depresses nitric oxide production [31, 32], and drugs having
antioxidant activity possess protective eﬀects against endo-
thelialdysfunction.Previousreportshaveindicatedthateach
component of the diagnostic criteria of metabolic syndromeEvidence-Based Complementary and Alternative Medicine 7
Table 4: Eﬀects of KBG on various parameters in group A (n = 27).
Period Week 0 Week 4 P-valuea P-valueb
BMI (kg/m2) KBG 24.1 ±0.62 4 .2 ±0.6 0.3362
0.6182
Control 24.2 ±0.72 4 .2 ±0.7 0.5916
Waist circumference (cm) KBG 85.6 ±1.88 5 .8 ±2.0 0.6699
0.9871
Control 87.2 ±1.98 7 .3 ±1.9 0.8962
SBP (mmHg) KBG 126.3 ±3.2 125.4 ±3.2 0.6820
0.9476
Control 122.6 ±2.8 121.5 ±2.8 0.5591
DBP (mmHg) KBG 76.3 ±2.57 5 .9 ±2.0 0.3790
0.4292
Control 71.2 ±1.87 3 .3 ±1.7 0.3028
L RHI KBG 0.58 ±0.04 0.70 ±0.05 0.0231∗
0.0085∗∗
Control 0.65 ±0.05 0.55 ±0.04 0.1834
TG (mg/dL) KBG 129.2 ±14.6 128.1 ±12.7 0.7791
0.5937
Control 123.4 ±11.0 116.6 ±8.9 0.5277
HDL-cholesterol (mg/dL) KBG 65.4 ±3.86 6 .0 ±3.6 0.8341
0.6859
Control 64.5 ±2.76 4 .5 ±2.4 0.8432
LDL-cholesterol (mg/dL) KBG 138.5 ±5.9 143.1 ±6.8 0.2268
0.0715
Control 130.5 ±5.3 127.3 ±5.5 0.1422
NEFA (μEq/L) KBG 527.8 ±49.1 445.4 ±33.9 0.0306∗
0.0004∗∗
Control 440.0 ±30.3 545.9 ±42.4 0.0028∗∗
FPG (mg/dL) KBG 103.7 ±3.3 105.9 ±4.6 0.3768
0.2550
Control 108.9 ±5.0 106.6 ±5.2 0.7477
IRI (μU/mL) KBG 6.71 ±0.58 6.05 ±0.58 0.0593
0.1223
Control 6.86 ±0.78 7.18 ±0.79 0.5777
HOMA-IR KBG 1.73 ±0.17 1.63 ±0.19 0.2001
0.3213
Control 1.91 ±0.26 2.00 ±0.30 0.4815
Creatinine (mg/dL) KBG 0.70 ±0.03 0.70 ±0.03 0.5742
1.0000
Control 0.71 ±0.03 0.71 ±0.04 0.9734
hs-CRP (mg/dL) KBG 0.10 ±0.03 0.10 ±0.02 0.1962
0.2681
Control 0.07 ±0.01 0.11 ±0.02 0.0423∗
MDA (nmol/mL) KBG 10.2 ±1.58 .7 ±1.4 0.0007∗∗
0.5068
Control 12.8 ±2.51 1 .9 ±2.1 0.3444
sVCAM-1 (ng/mL) KBG 769.5 ±72.6 708.2 ±66.3 0.0121∗
0.2791
Control 735.8 ±51.3 711.6 ±48.3 0.7389
KBG: keishibukuryogan; BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; L RHI, natural logarithmic scaled reactive
hyperemia; TG: triglyceride; HDL: high-density lipoprotein; LDL: low-density lipoprotein; NEFA: nonesteriﬁed fatty acid; FPG: fasting plasma glucose;
IRI: immunoreactive insulin; HOMA-IR: homeostasis model assessment as an index of insulin resistance; hs-CRP: high-sensitive C-reactive protein;M D A :
malondialdehyde; sVCAM-1: soluble vascular cell adhesion molecule 1.
aComparison between week 0 and week 4 by Wilcoxon signed-rank test.
bComparison of 4-week changes between KBG-treatment period and control period by MANOVA test.
Data are expressed as mean ± S.E., ∗P<0.05, ∗∗P<0.01.
is individually related to oxidative stress and endothelial dys-
function [33]. We reported the antioxidative eﬀect of KBG,
and this eﬀect is beneﬁcial for the prevention of endothelial
dysfunction and arteriosclerosis [9–12].
As for sVCAM-1, in our previous study dealing with
rheumatoidarthritispatients,KBGdecreasedtheplasmalev-
els of sVCAM-1 [34]. VCAM-1 is expressed on the impaired
endothelium is regulated by various factors such as oxidative
stress and cytokines [35, 36] and has been considered to be
an important risk factor to the progression of atherosclerosis
andcardiovascularevents[37].Inthepresentstudy,thevalue
of sVCAM-1 was decreased by KBG-treatment in group A.
We speculated that the antioxidant eﬀect of KBG might lead
to the downregulation of VCAM-1.8 Evidence-Based Complementary and Alternative Medicine
Table 5: Eﬀects of KBG on various parameters in group B (n = 22).
Period Week 0 Week 4 P-valuea P-valueb
BMI (kg/m2) Control 22.8 ±0.62 2 .7 ±0.6 0.4477
0.3443 KBG 22.7 ±0.62 2 .7 ±0.6 0.7660
Waist circumference (cm) Control 82.7 ±1.78 2 .8 ±1.6 0.9129
0.8807 KBG 84.1 ±1.58 4 .1 ±1.3 0.8125
SBP (mmHg) Control 123.8 ±2.6 122.5 ±2.3 0.4676
0.0808 KBG 123.4 ±3.3 115.5 ±2.2 0.0037∗∗
DBP (mmHg) Control 75.7 ±2.27 5 .2 ±1.6 0.5524
0.7949 KBG 72.5 ±1.87 1 .5 ±1.9 0.1567
L RHI Control 0.62 ±0.05 0.66 ±0.05 0.2870
0.1751 KBG 0.56 ±0.05 0.70 ±0.05 0.0074∗∗
TG (mg/dL) Control 128.3 ±14.7 122.2 ±8.6 0.9750
0.7320 KBG 118.4 ±8.4 117.2 ±7.8 0.9251
HDL-cholesterol (mg/dL) Control 60.4 ±3.25 7 .7 ±3.1 0.0718
0.3085 KBG 57.8 ±3.25 7 .2 ±3.3 0.4357
LDL-cholesterol (mg/dL) Control 132.6 ±8.0 128.2 ±9.0 0.1619
0.7604 KBG 125.5 ±7.7 122.5 ±6.7 0.5393
NEFA (μEq/L) Control 590.5 ±56.6 509.5 ±39.0 0.1289
0.9939 KBG 539.1 ±42.8 457.7 ±41.0 0.0312∗
FPG (mg/dL) Control 101.4 ±2.69 8 .8 ±2.5 0.0881
0.6065 KBG 97.6 ±2.99 6 .1 ±2.7 0.1706
IRI (μU/mL) Control 5.51 ±0.63 5.12 ±0.59 0.1525
0.2374 KBG 4.53 ±0.50 4.76 ±0.44 0.6260
HOMA-IR Control 1.42 ±0.19 1.28 ±0.17 0.1342
0.2206 KBG 1.12 ±0.14 1.15 ±0.12 0.8140
Creatinine (mg/dL) Control 0.71 ±0.03 0.70 ±0.03 1.0000
0.4789 KBG 0.74 ±0.04 0.75 ±0.04 0.7539
hs-CRP (mg/dL) Control 0.16 ±0.07 0.09 ±0.04 0.4895
0.4382 KBG 0.17 ±0.10 0.16 ±0.07 0.8877
MDA (nmol/mL) Control 13.1 ±2.81 2 .8 ±3.3 0.6747
0.0464∗
KBG 13.7 ±1.71 0 .5 ±1.4 <0.0001∗∗
sVCAM-1 (ng/mL) Control 710.1 ±50.7 716.9 ±56.4 0.4684
0.3898 KBG 666.1 ±36.3 640.3 ±41.4 0.3021
KBG: keishibukuryogan; BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; L RHI: natural logarithmic scaled reactive
hyperemia; TG: triglyceride; HDL: high-density lipoprotein; LDL: low-density lipoprotein; NEFA, nonesteriﬁed fatty acid; FPG: fasting plasma glucose;
IRI: immunoreactive insulin; HOMA-IR: homeostasis model assessment as an index of insulin resistance; hs-CRP: high-sensitive C-reactive protein;M D A :
malondialdehyde; sVCAM-1: soluble vascular cell adhesion molecule 1.
aComparison between week 0 and week 4 by Wilcoxon matched-pairs signed-ranks test.
bComparison of 4-week changes between control period and KBG-treatment period by MANOVA test.
Data are expressed as mean ± S.E., ∗P<0.05, ∗∗P<0.01.
From the results of the present study, it is suggested that
KBGhasthepotential topreventtheprogressionofendothe-
lial dysfunction and arteriosclerosis by its antioxidative ef-
fect, and early detection of endothelial dysfunction with
PAT and early treatment with KBG might contribute to the
prevention of arteriosclerosis.
5. Conclusion
Our present controlled clinical trial with crossover design
revealed that KBG improves endothelial function as evalu-
ated by L RHI in patients with metabolic syndrome-related
factors, suggesting that KBG has beneﬁcial eﬀects against the
progression of endothelial dysfunction and arteriosclerosis.
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